Why the study?
Do anticoagulant drugs targeting FXa accelerate fibrinolysis compared to those targeting tissue factor or thrombin in a plasma-based clot lysis assay?
Population
Plasma-based clot lysis assay (in vitro model)
Comparison
Anticoagulant drugs targeting activated factor X vs Anticoagulant drugs targeting tissue factor or…
Design
Preclinical
Authors
Loading...
Hypothesis-generating for FXa-specific fibrinolysis acceleration in vitro; prospective studies needed before clinical translation.
Do anticoagulant drugs targeting FXa accelerate fibrinolysis compared to those targeting tissue factor or thrombin in a plasma-based clot lysis assay?
In vitro, FXa inhibitors uniquely accelerate fibrinolysis compared to direct thrombin or tissue factor inhibitors, suggesting a distinct mechanism that may influence both thrombolysis efficacy and bleeding risk.
Lisman et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: